Shares of Intercept Pharmaceuticals Inc. (ICPT) slipped over 8% on Wednesday morning after the company announced convertible notes exchange, new issuance and stock repurchase.
ICPT is currently trading at $15.35, down $1.40 or 8.36%, on the Nasdaq, on a volume of 5.2 million shares, far above the three-month average volume of 693 thousand shares. Intercept has traded between $13.88 and $54.26 in the 52-week period. The stock has lost nearly 70% in that time frame.
The company said it has agreed with certain of the holders of its existing 3.25% Convertible Senior Notes due 2023 and 2.00% Convertible Senior Notes due 2026 to exchange $306.5 million principal amount of 2023 Notes and $114.7 million principal amount of 2026 notes for a newly issued series of Convertible Senior Secured Notes due 2026.
Intercept will also sell about $117.6 million new Notes for cash.
Intercept estimates that cash proceeds will be about $107.3 million and to use the proceeds for general corporate purposes.
Intercept expects to use $75.7 million of cash on hand to repurchase shares of its common stock in privately negotiated transactions at a price per share of $16.75, equal to the closing price of the Company's common stock on August 10, 2021.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.